{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T23:04:33Z","timestamp":1784761473952,"version":"3.55.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Chugai Pharmaceutical Co., Ltd"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>T-cell engager therapies, including CD3-bispecific antibodies, have demonstrated potent antitumor activity but frequently cause cytokine release syndrome (CRS). CRS is a systemic inflammatory response characterized by high levels of circulating cytokines and immune-cell hyperactivation, with symptoms ranging from mild features such as fever and fatigue to severe, life-threatening conditions including shock and multiorgan failure. Currently, both prophylactic measures and prompt post-onset treatment are essential for therapy with T-cell engagers. Although CRS mitigation strategies reduce its incidence and severity, marked interindividual variability in CRS remains: Some patients show no symptoms, whereas others develop severe symptoms under identical preventive measures. This study aimed to elucidate the mechanisms underlying the interindividual variability in cytokine release and cytotoxicity following stimulation with a T-cell engager. We used ERY22, a T-cell engager developed as a monkey surrogate of the human therapeutic candidate ERY974, an anti-GPC3\/CD3 T-cell engager. ERY22 has been previously reported to induce severe CRS in cynomolgus monkeys following in vivo administration. When PBMCs from 16 cynomolgus monkeys and GPC3-expressing target cells were co-cultured ex vivo with ERY22, there was substantial interindividual variability in cytokine production and cytotoxicity. We hypothesized that epigenetic states in T cells modulate these responses; accordingly, we profiled pretreatment T-cell chromatin accessibility using ATAC-seq. Interindividual variability in cytokine production and cytotoxicity correlated with chromatin accessibility at loci associated with these processes. These findings advance understanding of personalized risk prediction and management of CRS in clinical settings.<\/jats:p>","DOI":"10.1093\/toxsci\/kfag076","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T16:52:06Z","timestamp":1782751926000},"source":"Crossref","is-referenced-by-count":0,"title":["T-cell chromatin states reflect individual differences in\n                    <i>ex viv<\/i>\n                    o cytokine release and cytotoxicity induced by T-cell engager ERY22 in cynomolgus monkeys"],"prefix":"10.1093","volume":"209","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4708-8658","authenticated-orcid":false,"given":"Yoshika","family":"Iwata","sequence":"first","affiliation":[{"name":"Translational Research Division, Chugai Pharmaceutical Co., Ltd , Yokohama 244-0003,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Narushima","sequence":"additional","affiliation":[{"name":"Research Division, Chugai Pharmaceutical Co., Ltd , Yokohama 244-0003,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asako","family":"Harada","sequence":"additional","affiliation":[{"name":"Translational Research Division, Chugai Pharmaceutical Co., Ltd , Yokohama 244-0003,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihisa","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Research Division, Chugai Pharmaceutical Co., Ltd , Yokohama 244-0003,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Ikegami","sequence":"additional","affiliation":[{"name":"Translational Research Division, Chugai Pharmaceutical Co., Ltd , Yokohama 244-0003,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Mishima","sequence":"additional","affiliation":[{"name":"Translational Research Division, Chugai Pharmaceutical Co., Ltd , Yokohama 244-0003,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Translational Research Division, Chugai Pharmaceutical Co., Ltd , Yokohama 244-0003,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"2026072218370395900_kfag076-B1","doi-asserted-by":"publisher","first-page":"4785","DOI":"10.1158\/1078-0432.CCR-18-0455","article-title":"CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies","volume":"24","author":"Bacac","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2026072218370395900_kfag076-B2","doi-asserted-by":"publisher","first-page":"2181016","DOI":"10.1080\/19420862.2023.2181016","article-title":"Strategies for clinical dose optimization of T cell-engaging therapies in oncology","volume":"15","author":"Ball","year":"2023","journal-title":"mAbs"},{"key":"2026072218370395900_kfag076-B3","doi-asserted-by":"publisher","first-page":"7137900","DOI":"10.1155\/2022\/7137900","article-title":"Potential pathophysiological mechanisms underlying multiple organ dysfunction in cytokine release syndrome","volume":"2022","author":"Chen","year":"2022","journal-title":"Mediators Inflamm"},{"key":"2026072218370395900_kfag076-B4","doi-asserted-by":"publisher","first-page":"4180","DOI":"10.1182\/bloodadvances.2020002565","article-title":"AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys","volume":"4","author":"Goldstein","year":"2020","journal-title":"Blood Adv"},{"key":"2026072218370395900_kfag076-B5","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.1182\/bloodadvances.2023011089","article-title":"Predictive model for the risk of cytokine release syndrome with glofitamab treatment for diffuse large B-cell lymphoma","volume":"8","author":"Gritti","year":"2024","journal-title":"Blood Adv"},{"key":"2026072218370395900_kfag076-B6","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s11899-018-0472-8","article-title":"Bispecific antibodies for the treatment of acute myeloid leukemia","volume":"13","author":"Guy","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"2026072218370395900_kfag076-B7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3389\/fonc.2014.00063","article-title":"Blinatumomab, a bi-specific anti-CD19\/CD3 BiTE antibody for the treatment of acute lymphoblastic leukemia: perspectives and current pediatric applications","volume":"4","author":"Hoffman","year":"2014","journal-title":"Front Oncol"},{"key":"2026072218370395900_kfag076-B8","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026072218370395900_kfag076-B9","doi-asserted-by":"publisher","first-page":"eaal4291","DOI":"10.1126\/scitranslmed.aal4291","article-title":"An anti-glypican 3\/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors","volume":"9","author":"Ishiguro","year":"2017","journal-title":"Sci Transl Med"},{"key":"2026072218370395900_kfag076-B10","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1002\/jat.4812","article-title":"Antitumor cytotoxic activity retained in tolerized T cells following daily dose escalation of a T-cell engager in cynomolgus monkeys to mitigate cytokine release syndrome","volume":"45","author":"Iwata","year":"2025","journal-title":"J Appl Toxicol"},{"key":"2026072218370395900_kfag076-B11","doi-asserted-by":"publisher","first-page":"115986","DOI":"10.1016\/j.taap.2022.115986","article-title":"Priming treatment with T-cell redirecting bispecific antibody ERY974 reduced cytokine induction without losing cytotoxic activity in vitro by changing the chromatin state in T cells","volume":"441","author":"Iwata","year":"2022","journal-title":"Toxicol Appl Pharmacol"},{"key":"2026072218370395900_kfag076-B12","doi-asserted-by":"publisher","first-page":"114657","DOI":"10.1016\/j.taap.2019.114657","article-title":"Daily ascending dosing in cynomolgus monkeys to mitigate cytokine release syndrome induced by ERY22, surrogate for T-cell redirecting bispecific antibody ERY974 for cancer immunotherapy","volume":"379","author":"Iwata","year":"2019","journal-title":"Toxicol Appl Pharmacol"},{"key":"2026072218370395900_kfag076-B13","doi-asserted-by":"publisher","first-page":"2040620719899897","DOI":"10.1177\/2040620719899897","article-title":"Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia","volume":"11","author":"Jain","year":"2020","journal-title":"Ther Adv Hematol"},{"key":"2026072218370395900_kfag076-B14","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1038\/s12276-023-01105-x","article-title":"CD8 T-cell subsets: heterogeneity, functions, and therapeutic potential","volume":"55","author":"Koh","year":"2023","journal-title":"Exp Mol Med"},{"key":"2026072218370395900_kfag076-B15","doi-asserted-by":"publisher","first-page":"12312","DOI":"10.1038\/s41598-022-16564-x","article-title":"Determination of starting dose of the T cell-redirecting bispecific antibody ERY974 targeting glypican-3 in first-in-human clinical trial","volume":"12","author":"Komatsu","year":"2022","journal-title":"Sci Rep"},{"key":"2026072218370395900_kfag076-B16","doi-asserted-by":"publisher","first-page":"4449","DOI":"10.1158\/1078-0432.CCR-22-3667","article-title":"Dissecting the mechanisms underlying the cytokine release syndrome (CRS) mediated by T-cell bispecific antibodies","volume":"29","author":"Leclercq-Cohen","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026072218370395900_kfag076-B17","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"2026072218370395900_kfag076-B18","doi-asserted-by":"publisher","first-page":"3880","DOI":"10.1128\/MCB.00592-15","article-title":"Long-range transcriptional control of the IL2 gene by an intergenic enhancer","volume":"35","author":"Mehra","year":"2015","journal-title":"Mol Cell Biol"},{"key":"2026072218370395900_kfag076-B19","doi-asserted-by":"publisher","first-page":"462","DOI":"10.3389\/fimmu.2015.00462","article-title":"Transcriptional enhancers in the regulation of T cell differentiation","volume":"6","author":"Nguyen","year":"2015","journal-title":"Front Immunol"},{"key":"2026072218370395900_kfag076-B20","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.3390\/cancers14102516","article-title":"Glofitamab treatment in relapsed or refractory DLBCL after CAR T-cell therapy","volume":"14","author":"Rentsch","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026072218370395900_kfag076-B21","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.yrtph.2017.09.001","article-title":"An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection","volume":"90","author":"Saber","year":"2017","journal-title":"Regul Toxicol Pharmacol"},{"key":"2026072218370395900_kfag076-B22","doi-asserted-by":"crossref","first-page":"CT111","DOI":"10.1158\/1538-7445.AM2021-CT111","article-title":"Results of a phase 1 dose escalation study of ERY974, an anti-glypican 3 (GPC3)\/CD3 bispecific antibody, in patients with advanced solid tumors","volume":"81","author":"Safran","year":"2021","journal-title":"Cancer Res"},{"key":"2026072218370395900_kfag076-B23","doi-asserted-by":"publisher","first-page":"5265","DOI":"10.1038\/s41467-022-32952-3","article-title":"Combination of T cell-redirecting bispecific antibody ERY974 and chemotherapy reciprocally enhances efficacy against non-inflamed tumours","volume":"13","author":"Sano","year":"2022","journal-title":"Nat Commun"},{"key":"2026072218370395900_kfag076-B24","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.3390\/cancers15102824","article-title":"T-cell engagers in solid cancers-current landscape and future directions","volume":"15","author":"Shanshal","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026072218370395900_kfag076-B25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2026072218370395900_kfag076-B26","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ymeth.2018.10.005","article-title":"Engineering a bispecific antibody with a common light chain: identification and optimization of an anti-CD3 epsilon and anti-GPC3 bispecific antibody, ERY974","volume":"154","author":"Shiraiwa","year":"2019","journal-title":"Methods"},{"key":"2026072218370395900_kfag076-B27","doi-asserted-by":"publisher","first-page":"6083","DOI":"10.1158\/1078-0432.CCR-21-0470","article-title":"Cytokine release syndrome by T-cell-redirecting therapies: can we predict and modulate patient risk?","volume":"27","author":"Van De Vyver","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026072218370395900_kfag076-B28","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/s41590-021-01086-x","article-title":"Hierarchical regulation of the resting and activated T cell epigenome by major transcription factor families","volume":"23","author":"Zhong","year":"2022","journal-title":"Nat Immunol"},{"key":"2026072218370395900_kfag076-B29","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40364-021-00294-9","article-title":"The landscape of bispecific T cell engager in cancer treatment","volume":"9","author":"Zhou","year":"2021","journal-title":"Biomark Res"}],"container-title":["Toxicological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/toxsci\/advance-article-pdf\/doi\/10.1093\/toxsci\/kfag076\/68645831\/kfag076.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/toxsci\/article-pdf\/209\/7\/kfag076\/68645831\/kfag076.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/toxsci\/article-pdf\/209\/7\/kfag076\/68645831\/kfag076.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T22:37:08Z","timestamp":1784759828000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/toxsci\/article\/doi\/10.1093\/toxsci\/kfag076\/8721598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/toxsci\/kfag076","relation":{},"ISSN":["1096-0929"],"issn-type":[{"value":"1096-0929","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,6,29]]},"article-number":"kfag076"}}